ZEPP revenueFY2025$258.90M
- FY YoY
- +41.8%
- 5Y CAGR
- -23.5%
ZEPP revenue was $258.90M for fiscal 2025 (ended Dec 31, 2025), up 41.8% from fiscal 2024. Compound annual growth was -23.5% over 5 years. It rose in 4 of the last 8 fiscal years.
Zepp Health Corporation (ZEPP) financials
For fiscal 2025 (ended Dec 31, 2025), Zepp Health Corporation reported $258.90M of revenue and -$40.07M of net income.
- Revenue, FY2025
- $258.90M
- Revenue growth, YoY
- +41.8%
- Net income, FY2025
- -$40.07M
- Net margin
- -15.5%
- Free cash flow, FY2025
- -$26.21M
- EPS, diluted, FY2025
- -$0.16
- Cash
- $57.05M
- Total debt
- $59.48M
- P/S
- 0.13
- Market cap
- $33.0M
FY2017FY2025
FY2017FY2025
FY2017FY2025
ZEPP revenue and earnings growth
ZEPP net incomeFY2025-$40.07M
ZEPP net income was -$40.07M for fiscal 2025 (ended Dec 31, 2025), compared with -$75.73M in fiscal 2024.
ZEPP EPSFY2025-$0.16
ZEPP diluted EPS was -$0.16 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.29 in fiscal 2024.
ZEPP free cash flowFY2025-$26.21M
ZEPP free cash flow was -$26.21M for fiscal 2025 (ended Dec 31, 2025), compared with -$25.80M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $258.90M | $182.60M | $352.86M | $613.64M | $980.78M | $985.96M | $834.88M | $530.19M | $314.91M |
| Cost of revenue | $159.71M | $112.37M | $260.50M | $494.78M | $775.89M | $781.72M | $624.05M | $393.56M | $238.88M |
| Gross profit | $99.19M | $70.23M | $92.36M | $118.86M | $204.88M | $204.24M | $210.83M | $136.64M | $76.03M |
| Research and development | $45.32M | $46.16M | $51.50M | $77.30M | $80.83M | $82.45M | $61.88M | $38.28M | $23.64M |
| Selling, general and admin | $29.27M | $24.85M | $26.78M | $35.11M | $40.54M | $40.12M | $35.69M | $31.12M | $17.66M |
| Operating income | -$29.23M | -$47.25M | -$30.45M | -$61.86M | $14.74M | $26.70M | $87.12M | $53.19M | $27.97M |
| Interest expense | $5.70M | $5.55M | $6.75M | $8.44M | $7.04M | - | - | - | - |
| Pre-tax income | -$35.46M | -$57.90M | -$34.63M | -$55.89M | $16.74M | $40.71M | $93.71M | $56.23M | $29.49M |
| Income tax | $2.54M | $13.69M | -$2.43M | -$9.87M | $1.69M | $4.78M | $11.19M | $7.57M | $4.24M |
| Net income | -$40.07M | -$75.73M | -$31.02M | -$43.24M | $21.62M | $35.06M | $82.62M | $49.46M | $25.77M |
| EPS, basic | -$0.16 | -$0.29 | -$0.13 | -$0.18 | $0.09 | $0.14 | $0.34 | $0.08 | $0.10 |
| EPS, diluted | -$0.16 | -$0.29 | -$0.13 | -$0.18 | $0.08 | $0.13 | $0.32 | $0.07 | $0.10 |
| Diluted shares | 254.4M | 258.9M | 243.1M | 246.3M | 264.4M | 260.4M | 256.0M | 225.0M | 76.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $57.05M | $91.07M | $133.67M | $141.12M | $236.88M | $357.12M | $276.47M | $208.54M | $53.74M |
| Short-term investments | - | $997.0K | $5.15M | $4.97M | $3.04M | $2.83M | $2.47M | $7.34M | $2.11M |
| Receivables | $66.91M | $62.97M | $60.73M | $98.90M | $84.28M | $45.68M | $27.14M | $8.57M | $5.05M |
| Inventory | $72.76M | $56.79M | $84.89M | $148.16M | $196.05M | $186.60M | $128.39M | $70.48M | $38.38M |
| Current assets | $293.52M | $251.56M | $316.73M | $428.95M | $616.85M | $739.90M | $630.94M | $415.60M | $199.09M |
| Goodwill | $9.58M | $9.58M | $9.58M | $9.58M | $9.58M | $9.58M | $852.0K | $862.0K | $911.0K |
| Total assets | $564.84M | $528.59M | $635.52M | $763.74M | $954.95M | $904.78M | $743.31M | $473.93M | $225.25M |
| Current liabilities | $286.84M | $195.37M | $155.11M | $241.93M | $337.72M | $427.54M | $356.49M | $201.83M | $134.83M |
| Total debt | $59.48M | $75.24M | $120.02M | $99.20M | $114.06M | $9.20M | - | - | - |
| Total liabilities | $350.30M | $275.87M | $282.77M | $374.46M | $494.63M | $486.35M | $384.55M | $210.73M | $136.44M |
| Shareholders' equity | $214.53M | $251.59M | $352.75M | $389.28M | $460.32M | $418.43M | $359.21M | $263.39M | $34.70M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.69M | -$24.39M | $42.60M | -$117.11M | -$36.47M | $24.11M | $61.48M | $102.92M | $36.63M |
| Capital expenditures | $516.0K | $1.40M | $1.60M | $1.21M | $7.23M | $12.80M | $4.92M | $2.49M | $3.30M |
| Free cash flow | -$26.21M | -$25.80M | $41.01M | -$118.32M | -$43.70M | $11.30M | $56.55M | $100.42M | $33.34M |
| Investing cash flow | $1.48M | -$1.58M | $7.73M | -$6.24M | -$167.80M | -$31.70M | -$16.19M | -$47.25M | -$5.98M |
| Financing cash flow | $24.84M | $477.0K | -$41.68M | $42.37M | $86.48M | $86.54M | $3.68M | $92.96M | $3.09M |
| Dividends paid | - | - | - | $6.30M | - | - | $652.0K | - | - |
| Share repurchases | $1.24M | $2.28M | $2.52M | $8.16M | $2.16M | - | - | $1.19M | - |
| Stock-based compensation | $2.49M | $4.78M | $8.79M | $7.27M | $13.04M | $9.98M | $7.92M | $19.59M | $9.65M |
| Depreciation and amortization | $4.54M | $5.02M | $7.69M | $8.71M | $8.14M | $4.16M | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 41.8% | -48.3% | -42.5% | -37.4% | -0.5% | 18.1% | 57.5% | 68.4% | - |
| Net income growth, YoY | - | - | - | - | -38.3% | -57.6% | 67.1% | 91.9% | - |
| EPS growth, YoY | - | - | - | - | -38.5% | -59.4% | 357.1% | - | - |
| Gross margin | 38.3% | 38.5% | 26.2% | 19.4% | 20.9% | 20.7% | 25.3% | 25.8% | 24.1% |
| Operating margin | -11.3% | -25.9% | -8.6% | -10.1% | 1.5% | 2.7% | 10.4% | 10.0% | 8.9% |
| Net margin | -15.5% | -41.5% | -8.8% | -7.0% | 2.2% | 3.6% | 9.9% | 9.3% | 8.2% |
| Free cash flow margin | -10.1% | -14.1% | 11.6% | -19.3% | -4.5% | 1.1% | 6.8% | 18.9% | 10.6% |
| Return on equity | -18.7% | -30.1% | -8.8% | -11.1% | 4.7% | 8.4% | 23.0% | 18.8% | 74.3% |
| Return on assets | -7.1% | -14.3% | -4.9% | -5.7% | 2.3% | 3.9% | 11.1% | 10.4% | 11.4% |
| Current ratio | 1.02 | 1.29 | 2.04 | 1.77 | 1.83 | 1.73 | 1.77 | 2.06 | 1.48 |
| Debt to equity | 0.28 | 0.30 | 0.34 | 0.25 | 0.25 | 0.02 | - | - | - |
Source: XBRL data Zepp Health Corporation files with the SEC, latest filing dated Apr 24, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
ZEPP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ZEPP | $258.90M | +41.8% | -$40.07M | -15.5% | $33.0M |
| AAPL | $478.83B | +15.1% | $132.18B | 27.6% | $4.98T |
| IBM | $69.87B | +6.8% | $11.17B | 16.0% | $231.55B |
| DELL | $151.20B | +49.0% | $11.38B | 7.5% | $208.88B |
| HPQ | $59.16B | +8.1% | $2.45B | 4.1% | $25.66B |
| SMCI | $53.99B | +156.5% | $3.66B | 6.8% | $18.89B |
| OMCL | $1.24B | +5.6% | $44.66M | 3.6% | $1.72B |
| OSS | $41.99M | - | $429.3K | 1.0% | $107.8M |
ZEPP FAQ
9 questionsWhat is ZEPP revenue?
Zepp Health Corporation (ZEPP) reported $258.90M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 41.8% from the year before.Is ZEPP profitable?
No. Zepp Health Corporation reported a net loss of $40.07M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ZEPP have?
Zepp Health Corporation reported $57.05M in cash and cash equivalents and $59.48M of debt on its most recent balance sheet in SEC filings.How fast is ZEPP revenue growing?
Zepp Health Corporation's revenue changed +41.8% in fiscal 2025, to $258.90M. Its compound annual growth rate was -23.5% over 5 years.What is ZEPP gross margin?
Zepp Health Corporation's gross profit was $99.19M on $258.90M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 38.3%.What is ZEPP free cash flow?
Zepp Health Corporation generated -$26.21M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$25.69M less capital expenditures.What is ZEPP earnings per share?
Diluted earnings per share were -$0.16 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ZEPP last report financial results?
The latest statements here come from Zepp Health Corporation's 20-F filed on Apr 24, 2026, covering the period ended Dec 31, 2025.Where does this ZEPP financial data come from?
Quantisnow builds these statements from the structured XBRL data Zepp Health Corporation files with the SEC. It is provided for information only and is not investment advice.